X
[{"orgOrder":0,"company":"Tarus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarus Therapeutics Seeks to Initiate Clinical Trial of TT-10 (A2AR antagonist) in Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA\u00ae (Pembrolizumab) in Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"Portage Biotech Announces $6.0 Million Registered Direct Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Tarus Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Provides Research and Development Update","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Portage Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for TT-10
Filters
Companies By Therapeutic Area
Details:
The Company intends to use the net proceeds for clinical development of TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $6.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
September 29, 2023
Details:
Under theagreement, Merck will provide KEYTRUDA for Portage's Phase 1a/1b trial evaluating adenosine 2A receptor antagonist candidate, TT-10 in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Lead Product(s):
TT-10 ,Pembrolizumab
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
September 05, 2023
Details:
TT-10 is an orally administered Portage’s adenosine 2A receptor (A2AR) antagonist candidate evaluating in patients with solid tumors including prostate cancer, renal and non-small cell lung cancer.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 26, 2023
Details:
TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Tarus Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 14, 2022
Details:
The application includes extensive preclinical data on TT-10's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.
Lead Product(s):
TT-10
Therapeutic Area: Oncology
Product Name: TT-10
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 10, 2021